GlaxoSmithKline to Implement Medidata Designer
Medidata Solutions announced that GlaxoSmithKline (GSK) has decided to implement Medidata Designer, a study design optimization solution, for its Clinical Research and Development organization. Using Designer, GSK can consistently design studies that meet key objectives and collect necessary data in a streamlined and efficient manner.
Medidata Designer drives study design quality with a CDISC-compliant data model that enforces the links across objectives, end points and procedures. This reusable metadata accelerates system setup, such as electronic data capture build, and automates the derivation of protocols and other key clinical deliverables. It improves compliance with standards, allows clinicians to focus on the science of clinical research and not on document management, and speeds study starts, shortening time to market for new therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
